There is an exponential increase in biological complexity as initial gene transcripts are spliced, translated into amino acid sequence, and post-translationally modified. Each protein can exist as multiple chemical or sequencespecific proteoforms, and each has the potential to be a critical mediator of a physiological or pathophysiological signaling cascade. Here, we provide an overview of how different proteoforms come about in biological systems and how they are most commonly measured using mass spectrometry-based proteomics and bioinformatics. Our goal is to present this information at a level accessible to every scientist interested in mass spectrometry and its application to proteome profiling. We will specifically discuss recent data linking various protein post-translational modifications to cardiovascular disease and conclude with a discussion for enablement and democratization of proteomics across the cardiovascular and scientific community. The aim is to inform and inspire the readership to explore a larger breadth of proteoform, particularity post-translational modifications, related to their particular areas of expertise in cardiovascular physiology. (Circ Res.
T he capability to sequence whole genomes has led to an explosion in the basic and translational understanding about how nucleotide sequences are associated with or predictive of a multitude of cardiovascular phenotypes. 1 Knowledge of DNA sequence variants, however, provides only a partial and often static understanding of how differences in genetic code translate to the reality of physiology and pathophysiology. Linking other intrinsic environmental and lifestyle factors acting at the level of transcriptional, translational, cotranslational and posttranslational physiology is a key aim to provide an integrative framework for systemic analysis of cellular homeostasis and disease. Collectively, these variants of amino acid sequences and their chemical modifications are referred to as the proteoforms of any single primary nucleotide sequence encoded in the genome. 2 Thus, proteoforms exist as both structural variants and post-translationally modified variations. There has been recent attention given to the importance of considering splicing, cleavage, and other structural isoforms in cardiovascular physiology, including a profiling of apolipoprotein isoforms, 3 LOX1 (lysyl oxidase 1) isoforms as they relate to atherosclerosis, 4 the role of RBM20 (RNA-binding protein 20) and sarcomeric splice isoforms during dilated cardiomyopathy, 5 and profiling myofilament isoforms, 6 as well as their phosphorylation state as they change after myocardial infarction. 7 Because any one or a combination of proteoforms could be the critical diagnostic or therapeutic target for a specific cardiovascular condition, we contend that attention should be given to the profiling, quantifying, and understanding of proteoform complexity within cardiovascular systems. In this review, we will (1) focus on 1 type of proteoforms, protein posttranslational modification (PTM); (2) describe how biochemistry and mass spectrometry (MS) are harnessed to profile, detect and quantify proteins and PTMs; and (3) provide examples of PTMs, including understudied PTMs already shown to be clinically relevant in cardiovascular disease. It is our goal to enhance the understanding of the current state of the art for PTM proteomics among basic and clinical cardiovascular scientists. We hope that these efforts will lead to a broader appreciation of the need to embrace the complexity inherent to protein biochemistry and its relevance to disease diagnosis and therapeutics.
Proteoforms-Definition and Scope
Proteoforms represent all possible variants of a single gene product and include both differences in amino acid sequence (eg, isoforms and cleavage products) and chemical modifications of amino acid residues. They represent an important mechanism for diversifying and regulating the cellular proteome and can dramatically increase the chemical diversity of a protein. Knowledge and quantification of protein substrates and their PTM sites is key to dissecting PTM-mediated cellular processes, including complex regulatory networks. Despite their importance, the comprehensive identification and discovery of PTMs in complex biological samples has continued to pose challenges for proteomics technologies. 8 A PTM is a covalent process resulting from a proteolytic cleavage or from the addition of a modifying group to a particular amino acid. The chemical nature and function of these modifications is diverse. They include covalent additions of particular chemical groups (eg, phosphoryl), lipids (eg, palmitic acid), carbohydrates (eg, glucose), or even entire proteins (eg, ubiquitin) to amino acid side chains. 9 PTMs frequently affect certain groups of amino acid residues, for instance, phosphorylation affects serine (S), threonine (T), and tyrosine (Y); acetylation and ubiquitination occur on lysine (K), and methylation occurs on lysine (K) and arginine (R) residues. Moreover, many amino acid residues can have >1 type of PTM ( Figure 1 ). Some PTMs involve reversible reactions mediated by chemical moieties (eg, cysteine oxidation), whereas others occur via systems of enzymes that recognize short linear motifs in substrate proteins, to add and remove the PTM (eg, the specific kinases and phosphatase that regulate phosphorylation). Other PTMs are irreversible and cycle only with de novo synthesis of the protein (eg, citrullination). Regardless of the mechanism of PTM regulation, the results of these processes are that the proteome of a cell or organism has vastly more components than there are genes encoding them. To date, there are >600 different PTMs assigned in the UniProt database; with >100 different modifications reported in human proteins. [10] [11] [12] [13] In addition to the considerable diversity of characterized PTMs, it has become clear that some PTMs can exist in a reciprocal or associational relationship within a protein's amino acid sequence to further regulate its function. [17] [18] [19] [20] The role of this PTM crosstalk is still not well understood, in part, because of a lack of tools. However, successful attempts in developing in silico algorithms that can reliably predict various PTMs in a given protein based on residues surrounding a modification site can help to understand the co-occurrence of the different PTMs on the same protein. 21, 22 In fact, cross talk has also been observed between PTMs located on interacting proteins; however, deciphering the timing and extent of possible PTM combinations has been challenging. 18, 23 A further challenge in the large-scale proteomic approach to identifying and meaningfully interpreting PTMs biologically is that many of the sites discovered in the last decade have not yet been integrated in any specific pathway.
In the following sections, we describe some of the available MS methods, online platforms, and their contribution in the study of PTMs. This effort is an attempt to establish a stronger link between the path to comprehensive proteoform analysis and the biological functions they confer.
Analysis of PTMs and Proteomes by MS
During the last 30 years, experimental techniques used for mapping and quantifying PTMs have undergone impressive progress. Still there are many PTMs that do not have easy-touse tools or any understanding of their regulation or role in biology. In the following section, we will outline the several different MS approaches that have emerged to identify and quantify peptides and their modified forms by MS. 24 PTMs can be studied using 2 basic MS strategies: a top-down approach, which measures the mass of intact proteins, or a bottom-up approach, which measures proteolytically derived peptides. Although the sample preparation and the data interpretation differentiate the top-down and bottom-up approaches, the basic concepts of how ions are surveyed, selected, and fragmented and how this process can be optimized for PTM discovery is somewhat generalizable across approaches, and we will begin this section with a brief overview of these technical concepts and consideration.
The combination of liquid chromatography (LC) and tandem MS/MS is now a standard technology frequently applied to high-throughput peptide and protein identification and quantification. [25] [26] [27] Tandem mass spectrometers perform 2 basic measurements as peptides are being eluted from the LC column. First, in the parent or MS1 scan, the mass is determined for each peptide present in a sampling of the eluting intact peptides from the chromatophic separation at a given point in time. Second, in the MS/MS, sometimes referred to as MS2 scan, ≥1 parent peptides are split into pieces using 1 of several different strategies to break the chemical bonds between amino acids (eg, collision with inert gases or transfer of electrons). This results in generation of multiple fragments of the original peptide that are again detected and quantified in the mass spectrometer (eg, the fragment masses). The combination of the parent mass and its associated fragment masses can be used to determine the sequence of the peptide, amino acid localization of its PTMs, and ultimately match its sequence to a protein gene product from a genomic database. This basic process is the foundation for the 3 common variants of bottom-up proteomics: data-dependent acquisition (DDA), data-independent acquisition (DIA), and targeted acquisition (which can consist of multiple reaction monitoring, selective reaction monitoring, or parallel reaction monitoring, respectively). Figure 2 and Table 1 illustrate the defining characteristics and provide a summary of the strengths and weakness of each approach, respectively. DDA attempts to isolate and sequence every peptide individually. This method is also referred to as shotgun proteomics and is the most commonly used approach. 27 DDA involves cycling between detecting the intact parent peptide (eg, MS1 ions) and then the instrument selecting a subset of individual Nonstandard Abbreviation and Acronyms
Tn troponin peptide (MS1) ions for further fragmentation (eg, MS/MS). Importantly, this approach requires a decision by the instrument in each cycle as to which MS1 ions to select and filter for fragmentation. Despite ever increasing sensitivity and cycling speed of DDA when implemented on modern mass spectrometers, 45 its semistochastic nature leads to sampling of a slightly Figure 1 . Examples of post-translational modifications, the amino acids they target, and their categories.
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different subset of peptides each time a sample is analyzed, resulting in missing peptide identifications and decreased reproducibility across multiple runs or experimental samples. But importantly, it is the only way to find novel proteins that are present in any particular sample. 29, 46 As an alternative to DDA, DIA is an approach that improves data completeness by not programming the instrument to isolate selected precursors for fragmentation but sweeping through a preset precursor mass range, filtering groups of intact peptides for fragmentation. 32, 47, 48 Each MS/MS spectra generated produces a convoluted mix of the fragments derived from all peptides isolated within a given mass window at a given time in the LC gradient. Peptide and ultimately protein identifications are determined by comparing the acquired data against a previously established library of expected fragments and the discrete time they are expected to elute along the chromatogram (eg, retention time). 49 This means that only those proteins and their selected peptides will be analyzed. Therefore, you can miss novel proteins that maybe present in samples if they are not included in the library.
In theory, because all peptides are fragmented and thereby sequenced, the digital record of the complete peptide contents of the sample is created. 50 However, this makes it complicated, and ensuring the correct peptide identification becomes critical. 45 The benefit to this approach is that as every precursor mass range is fragmented in every sample, there should be fewer gaps in the data and improved run-to-run reproducibility. 51, 52 Finally, although DIA has been gradually accepted by the proteomics community, the sensitivity for detecting low abundant protein and PTMs is still challenged by signal-to-noise limitations and library composition and completeness. 53, 54 Targeted MS is the third category of bottom-up analysis and is more closely related to ELISA (enzyme-linked immunosorbent assay) and Western blots, in that predefined protein(s) is analyzed or quantified. With this method, a sample is queried for the presence and quantity of specific peptides, unique to the protein of interest, and the instrument hones in on only a few characteristic fragments of these peptides. Thus, the mass spectrometer only allows those prespecified peptides (based on their mass) to be detected. The time the instrument has to dwell on any 1 peptide is increased compared with the other methods, and this results in a greater sensitivity over the other untargeted acquisition modes. 55 For specific, precise quantification, reproducibility, and validation of circulating biomarkers, this targeted mode of LC-MS/MS has been the standard. 37, 41 A variant of multiple-reaction monitoring that may be important for the analysis of PTMs is parallel-reaction monitoring. 56 In parallel-reaction monitoring, the precursor ion is targeted, but data are collected on all of the resulting fragment ions. The key advantage over traditional multiple-reaction monitoring is specificity because all potential product ions of a peptide are available to unambiguously confirm the identity of the peptide and, in the case of PTMs, potentially also confirm the site of chemical modification (as discussed below). 56 Furthermore, monitoring of all transitions does not require prior knowledge or optimization of target transitions, minimizing upfront development time and enabling more flexible data analysis.
In contrast to these bottom-up approaches, with top-down proteomics, intact proteins are first detected in a parent MS1 scan and subsequently isolated and fragmented as described above to identify component peptides, deduce their amino acid sequences, and sites of PTM. Top-down is perhaps the only technique capable of truly detecting all of the combinations of PTMs present in a system at a given sampling time in their relative quantities. 57 A close correlate of top-down is middledown in which the protein is digested up into larger fragments than a typical tryptic digest to both improve ionizability and yet retain the potential for mapping some of the different combinations of PTMs present on a protein in a given system. 58 In addition to multiple, more generalized predecessors, 59 a recent and thorough review by Cai et al 57 elegantly summarizes the concepts, technical considerations, and contributions of topdown proteomics specifically in the understanding of proteoforms and PTMs in cardiovascular biology and disease.
Regardless of whether top-down or bottom-up strategies are being used, an important additional consideration, particularly in reference to the PTM-proteome, is the mode of peptide (or protein, in the case of top-down) fragmentation used during MS2 acquisition. Although this topic is far too technical for in-depth consideration here, a brief review of fragmentation modes and their benefits or drawbacks to PTM discovery is warranted. Fragmentation approaches within the MS include physical methods dependent on collision of ions with inert gases (eg, collision-induced dissociation [CID] and high-energy collision dissociation [HCD]) and energy transfer methods whereby more gentle or controllable electron transfer is used (eg, electron-transfer dissociation [ETD] ).
In the CID approach, fragmentation results from collision of the analyte with neutral gas. It is a low-energy process that breaks the peptide backbone at the C-N amide bond to form b-or y-type fragment ions, which are the most useful for determining the peptide sequence. 60 The downside of the method is that fragmentation of a peptide is size dependent because all the bonds of the peptide absorb the energy of the collision. Thus, in practice, if a peptide is >2500 Da, it is difficult to get enough energy into a single bond to break it. Moreover, labile PTMs like phosphorylation, glycosylation, or S-nitrosylation are often the first to absorb the energy and break from the peptide with CID, producing a dominant neutral loss ion of the original peptide parent mass and few subsequent fragment ions for sequence identification. Further, these more labile modifications are thus easily lost during CID fragmentation resulting in a lack of product ions that provided definitive evidence for the correct site of modification, ultimately limiting the ability to unambiguously assign the correct site of PTM (see more on this below). 61 In ETD, low-energy electrons are captured by peptide cations to form odd-electron peptides, which then dissociate to fragments primarily along the N-Cα bonds of the peptide backbone, generating c-and z-type ions. 62 Unlike CID processes, ETD cleavage does not increase the analyte's internal vibrational energy. 63 Therefore, the weakest bonds, such as labile phosphate bonds, are maintained. Ideally, for peptides with PTMs, ETD can provide both the sequence information for peptide identification and generation of product ions that are diagnostic for the modification site(s). 64 In the HCD approach, essentially the same collisional approach to fragmentation is used but with higher activation energy and shorter activation time comparing the traditional ion trap CID. Higher energy for HCD still generates b-and y-type fragment ions at typical peptide bonds but can also generate further fragmentation of peptide backbone, between the C-C bond, to form a-ions or smaller species. 65 Without the low-mass cutoff restriction and with high-mass accuracy MS2 spectra, HCD has been successfully applied for de novo peptide sequencing, providing more informative ion series. 43 Useful to study PTMs that are low in abundance 44 CID indicates collision-induced dissociation; DDA, data-dependent acquisition; DIA, data-independent acquisition; ETD, electron-transfer dissociation; HCD, highenergy collision dissociation; MRM, multiple reaction monitoring; PRM, parallel reaction monitoring; and PTM, post-translational modification.
As for PTMs studies, certain diagnostic ions specific for HCD can be recognized for PTM identification, like the 80-Da ion for phosphopeptides or the 204-Da O-GlcNAc oxonium ion. 66 The faster scan rate for HCD is expected to improve the identification coverage and accurate site localization for phosphoproteomics analysis.. 28 Today, a variety of hybrid mass spectrometers enable multiple types of MS/MS-allowing one to tailor the fragmentation method dynamically during a single experiment. 67 The ability of HCD to produce diagnostic product ions for a PTM has enabled a serial fragmentation workflow in which an initial HCD MS/MS run generates fragment data that, if the appropriate diagnostic low-mass ion for a given PTM is present, will subsequently trigger an additional ETD fragmentation event to accurately ascertain sequence and site specificity of the PTM(s) of interest. As an elegant example, this dual fragmentation approach has been used by Yin et al 68 to interrogate secreted glycoproteins from in vitro endothelial cells and extracellular matrix proteins associated with atrial fibrillation in human cardiac tissue.
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Informatic Considerations for PTM Data Analysis: What a Basic or Clinical Cardiovascular Scientist Should Know to Evaluate Proteomic PTM Data
Large-scale bioinformatic workflows are required to evaluate any data set and to gain new insight about changes in the proteome within a cell or tissue. The magnitude of data generated is the clear benefit but also the challenge of this approach for profiling proteoforms in biological systems. It can be daunting for scientists who do not have a background in MS-based proteomics or informatics to review and evaluate the quality of the data put forth in these types of studies. Apart from the same basic concepts of experimental design and proper use of positive and negative controls, there are a handful of additional generalizable concepts that can aid in demystifying the evaluation of proteomic PTM data quality. These include (1) understanding the quality of sequence identification(s), (2) assessment for how peptides were matched to proteins in bottom-up workflows or gene products from sequence databases in either bottom-up or top-down MS, (3) appropriate assurances that modifications are assigned to the correct amino acid, and (4) consideration of the assumptions made during data normalization and quantification. In the following paragraphs, each of these concepts will be briefly discussed. Because these categories apply to traditional bottom-up workflows, we will then finish with a brief discussion of top-down workflows and their application to the study of PTMs in cardiovascular biology.
Peptide Sequencing and Protein Matching
The biological importance of a presumed PTM is only as strong as the accuracy of its assignment to a given amino acid within a peptide or protein sequence and subsequent translated gene product. For bottom-up peptide sequence matching, each mode of MS data acquisition (eg, DDA, DIA, and targeted) uses slightly different assumptions, approaches, and assurances. In DDA experiments, peptide spectral matches are made by matching an observed fragment spectrum against a genomic sequence database using 1 of any number of available matching algorithms. 70, 71 The addition of PTM masses to this search process inflates the search space and increases the risk of false-positive matches. Similarly, modifications on lysines or arginines (eg, methylation, acetylation, and citrullination) can interfere with trypsin, causing missed cleavages that must also be accounted for informatically and can further increase search space and contribute to analytic processing demand, as well as impact the false-positive identification rate. To control for these false-positives, preliminary matches should then be subject to an additional false discovery rate assessment. 72, 73 Typically, a database of decoy sequences is generated by shuffling or reversing the sequences of the genomic database. 74 The score distribution of these false decoy sequences is used to assign the probability that a given peptide spectral match score of a target sequence is correct.
For DIA experiments, peptide sequences are assigned using a preexisting peptide library that defines both the intact peptide mass, with modification in the case of PTMs, as well as some number of common fragment masses. 49, 75, 76 The coelution of these 2 mass sets (eg, a whole peptide and its fragments) is a fundamental identifying feature. Multiple features of the coeluting MS1 and MS2 mass sets (eg, chromatographic behavior, signal-to-noise ratio, and fragment intensity) are scored accordingly and assembled into an overall metric that represents the quality of a potential peptide sequence match. These raw scores produced by the initial sequence-matching algorithms should be modeled against scores of decoy datasets, and researchers should report the probability or false discovery rate values used for assigning cutoffs. 77 Peptide identification using targeted acquisition is, in general, a simpler case because the predefined analysis is limited to only a few proteins (normally <100). Importantly, for optimal accuracy, an isotopically labeled internal standard peptide is included for each analyte that serves as both an identification and quantitative reference. 78 However, we encourage using internal standard peptides for all MS approaches for at least subsets of biologically important proteins.
In top-down proteomics, tandem MS/MS spectra tend to include larger fragments with higher charge states, and each fragment can be present in multiple isotope isomer forms. The isotopomer envelopes of 1 fragment from the intact protein often overlap with 1 or more others, and thus deconvolution of these complex spectra to derive the most common form of a given peptide isotope species is required and performed by various algorithms. [79] [80] [81] Once deconvoluted, the resulting mass lists can be assembled to predict the protein gene product that was selected for fragmentation during the MS1 step using a database search process roughly akin to that used to identify peptide sequences in bottom-up DDA analysis pipelines. [82] [83] [84] As with bottom-up workflows, searching of the data against a randomized or reversed database to derive false discovery rate prediction of a given protein identification by this pipeline is paramount to provide confidence limits to the identifications produced from automated, high-throughput workflows. 85 In all cases, often the final critical step before functional analysis is to assign peptide sequences to a specific gene product (eg, protein). Although simple in theory, there is considerable complexity in this process that warrants brief discussion here. Peptide sequences do not always uniquely match to a single gene product, and many closely related genes (eg, the actin and myosin gene families) have conserved sequences. Similarly, some post-transcriptional processing generates splice isoforms of the same gene product that further complicate simple matching of sequence-to-protein. Top-down proteomics is uniquely suited to identify the relative abundances of sequence proteoforms in a given sample because the protein species are directly observed intact during MS1 and not inferred by their predigested peptide components. 85 For bottom-up approaches, there is a healthy debate and several methods available for matching peptides to gene products for protein-level quantification that can be reviewed elsewhere. 86 In terms of PTMs, because the quantification step is often performed at the peptide level, it is less critical to the quantitative conclusions that the peptide be matched to a single proteoform. Making functional inferences as to the meaning of a given PTM difference between samples can be difficult if the peptide sequence in question is shared between many different gene products. Although there is no single way to best make the protein inferences in bottom-up proteomic workflows, researchers should be clear as to the assumptions and choices used in this process (eg, did the genomic sequence database contain isoforms or only canonical sequences and how were peptides matching multiple proteins handled).
Assurances Regarding Accurate Amino Acid Assignment of a Given PTM
The process of peptide spectral matching in all MS experiments will identify the presence of a given PTM(s) on a peptide sequence. However, if multiple residues within the same peptide are amenable to modification, there are additional steps required to assess certainty in PTM-site localization. For example, the phosphorylated activation sequence for ERK1 (mitogenactivated protein kinase 3; VADPDHDHTGFLTEYVATR) has 3 threonines and 1 tyrosine amenable to phosphorylation (underlined), whereas only 2 residues are critical for the protein's activation, as shown in bold. In all 3 modes of acquisition, the ability to determine whether an individual residue is modified depends on observing fragments that can distinguish one modified form of the peptide from its alternatives. For most methods, choosing the correct peptide fragment that contains the modified residues is required. 78 For DIA, there are at least 2 bioinformatics tools that can determine the confidence of a PTM assignment, 87, 88 whereas for DDA experiments, there are a handful of algorithms that score the confidence of site designation, including A score 89 and luciphor, 90 which assign probabilities of correct site assignment to the identified PTM peptides. All of these algorithms help increase the confidence of assigning which amino acid is modified. Top-down workflows use a conceptually similar approach, first identifying mass shifts between precursor ions (whole proteins in this case) and then using the presence or absence of a given PTM in various fragment ions from the MS/MS spectra to home in on the amino acid localization of the modification(s) present. This process is predicted from data analysis pipelines but often verified manually in top-down proteomics, and thus for review purposes, representation of the spectral data used to infer site localization may be important to validate particularly novel or biologically critical PTM events for the subsequent conclusions to be drawn by the researchers. 91 
Data Normalization and Quantification
A final set of considerations when evaluating proteomic PTM data involves how technical variability across samples was evaluated or normalized for and how the quantification of the PTM was done. 92 Many PTM workflows, both for bottom-up and top-down approaches, involve biochemical enrichment steps before MS analysis (see the next section), and these procedures introduce technical errors that can muddy the detection of biological differences between samples. 93 The use of isotopic labeling strategies like SILAC (stable isotope labeling of amino acids in cell culture) or peptide tagging can help to mitigate technical variation by enabling samples to be mixed before the enrichment workflow. 94 Alternatively, isotopically labeled control peptides or proteins can be spiked into samples to provide an index and normalization factor to account for sample preparation variance. At the least, assurances that the same amount of sample input was used at the outset of the preparation protocol, as well as a calculation of the technical variance inherent to the preparation protocol (eg, triplicate runs of 1 sample to determine technical coefficient of variation percentage), should be performed and reported. In bottomup proteomics, the question of whether to quantify the full PTM peptide species or each of the modified sites individually is an important consideration. Quantifying by site is a simpler approach but ignores the potential combinatorial relationships between multiple modification sites on the same protein. In bottom-up proteomics, inferring combinatorial relationships between PTM sites across different peptides from the same protein is challenging, whereas this is a defining strength of top-down approaches.
Finally, whether or not the PTM peptide should be normalized to the total nonmodified protein is a question to consider. For many PTM workflows, biochemical enrichment remains a prerequisite to obtain the sensitivity necessary for detecting and quantifying these typically lower abundant species. 40, 95 This process of enrichment uncouples the unmodified forms of the protein from the modified form, and this challenge may be a crippling limitation preventing the normalization of many PTM species identified in a discovery workflow. We recommend that the biological goal of the experiment be considered as well. If the goal is to know the signaling status in terms of the PTM forms present in a system, then knowing how much of the total protein is present is not as important because the active species is represented by the specific PTM forms. If, however, the goal is to monitor the signaling impact of a perturbation, specifically on increasing or decreasing the PTM state of the analytes, then knowing whether a change in a given PTM is because of a chemical modification rather than protein synthesis or degradation change is the key. In this case, it is mandatory to attempt to quantify total protein alongside PTM changes.
There are many factors to consider when evaluating the meaningfulness of PTM proteomic data. Our intention here was to simplify these considerations into key concepts to help basic and clinical cardiovascular scientists who are not experts at MS or proteomics to critically evaluate the data and ask appropriate questions of methodological assumptions.
PTM and Cardiovascular Physiology
PTMs have been found to exhibit a wide array of regulatory mechanisms in both physiological and pathological scenarios. Interestingly, a large number of PTMs are enriched and affected by inherited and somatic disease mutations. These disease-associated mutations change polarity, charge, and hydrophobicity of the wild-type amino acids in PTM sites making PTM variation more likely deleterious. 96, 97 There are several cases in which mutations of the post-translational target sites are directly involved in disease. For example, the Reimand group performed systematic studies of somatic cancer mutations affecting protein phosphorylation. Particularly, they were able to identify hot spots of disease mutation in PTM regions and disordered sequence. 98 The group highlighted 152 genes, called PTM-associated disease, where disease mutations, including cardiovascular (LMNA and MYH7), cystic fibrosis, diabetes mellitus (HNF4A and IRS1), migraine (ATP1A2), and cancer genes significantly accumulate in PTM regions. This study published a list of PTM-associated disease genes that potentially can serve as a starting point for investigating PTM mechanisms in many diseases. 96 In several other studies, somatic mutation was shown to affect multiple PTM target sites, including methylation, ubiquitination, and O-linked glycosylation, implicating all 3 modifications in disease. 99, 100 The discovery and characterization of more PTMs in a variety of physiological and pathological conditions generates valuable new knowledge, druggable targets, and biomarkers. Here, we will discuss a well-studied PTM, phosphorylation, and highlight some of the PTMs that have garnered less attention in the cardiovascular field but have no less potential for significant physiological insight. A summary of some of these modifications and the number of proteins they have been detected on that are related to cardiac function and disease is presented in Figure 3 .
Phosphorylation is arguably the most popular of PTMs analyzed in cardiovascular research and not without good cause. Phosphorylation is one of the best-understood mechanisms for intracellular signaling, its presence drives the activation, inhibition, stabilization, or degradation of kinases, enzymes, and other proteins, and it regulates myofilament stiffness, relaxation rate, and contractility. 101 For example, PLB (phospholamban) can be phosphorylated at Ser16 by PKA (protein kinase A) after β-adrenergic stimulation. This phosphorylation event relieves PLB's inhibitory effect on sarcoplasmic reticulum (SR) Ca 2+ -ATPase enhancing the SR Ca 2+ -ATPasedependent uptake of Ca 2+ to the SR. 102, 103 This modulation in calcium availability results in greater myocardial relaxation and contractility to improve cardiac output. Changes in phosphorylation status have also been linked to cardiovascular disease. Decreased phosphorylation of Tn (troponin) I at PKA sites (Ser22 and Ser23) and an increased phosphorylation of TnI by PKC (protein kinase C; Ser41, Ser43, and Thr142) were shown to be involved in heart failure. 104 There are also numerous examples of bottom-up phosphoproteomic studies in cardiovascular physiology and disease. All of these studies use a biochemical enrichment strategy to deplete the bulk of nonphosphorylated peptides, reducing sample complexity to devote more MS time to the analyte of interest and generally improve the signal-to-noise of the PTM peptide relative to the global proteome. 93, 105 Phospho-enrichment approaches include affinity-based methods that use antibodies generated to generalized modified epitopes (eg, pan-phosphotyrosine antibodies 106 ) or other chemicals with high affinity for the chemical properties of a given PTM (eg, metal affinity of TiO 2 (titanium dioxide) for binding phosphate groups in acid buffers 107, 108 ) although other specific enrichment approaches are discussed below. These studies targeting phosphorylation have revealed a variety of insight related to cardiovascular biology and disease. They include the relative nitric oxide (NO) independency of PDE9A (phosphodiesterase 9A) on cGMP (cyclic GMP) signaling by cardiomyocytes, 109 traced the β adrenergic signaling pathway in mouse heart tissue, 110 described the signaling response of vascular smooth muscle cells in response to stretch, 111 demonstrated novel components and potential therapeutic targets controlling platelet aggregation in response to ADP, 112 outlined the early phosphorylation events associated with ischemia-reperfusion injury in the heart, 113 profiled the phosphorylation sites present on β-AR (β-adrenergic receptors) in mouse, 114 distinguished ischemic from nonischemic end-stage heart failure in terms of phosphorylated protein signatures, and 115 identified the mitophagy regulator DRP1 (dynamin-related protein 1) as a key mediator of mouse hypertrophic cardiomyopathy. 116 Complementary examples from top-down proteomics have identified multiple phosphorylation states present on cardiac TnI that were capable of distinguishing between different types 117 and clinical stages 118 of heart failure, and profiled differences in myosin light chain isoforms and phosphorylation states between atrial and ventricular cardiac regions 119 that truncation of myosin-binding protein C results in its altered phosphorylation. 120 All this focused investigation has led to a wealth of cardiac-specific phospho-site information and the potential for tremendous insight into the regulation of these processes.
Beyond the well-characterized PTM, there lies a vast, largely unexplored landscape of other less-appreciated PTMs. One of the critical barriers to this investigation is technical. Without specific and robust tools to detect these other modifications, their study will be impeded and will lead to insight delay. We have chosen to focus on 3 emerging PTMs: S-nitrosylation, prenylation, and citrullination to provide an overview of the workflows currently used to detect them and some examples of the early insights for their importance in cardiovascular physiology.
S-nitrosylation (also known as S-nitrosation [SNO]
) is a redox-based modification where an NO group is added to the thiol moiety of a cysteine residue. 121 Although it is a covalent modification, it can be highly labile making it difficult to study using traditional techniques like Western blot and MS. In 2001, the Synder group introduced the biotin switch technique. 122, 123 At the time, this revolutionary new method selectively replaced the SNO modifications with a stable biotin group. This approach had 2 clear advantages: the labile SNO group was replaced with a more stable modification, and the biotin moiety provided a means for selective enrichment. Since this initial innovation, numerous iterations of the technique have been introduced. These tweaks to the protocol have focused on improving mapping the individual cysteine residues that are modified, quantifying the modified site between different samples and examining the extent of SNO occupancy of each modified cysteine under a given condition. [124] [125] [126] [127] [128] [129] [130] [131] [132] More thorough reviews of the techniques for detecting SNO modifications can be found here. [133] [134] [135] With the advent of all these technical advancements, the number of characterized SNO sites has increased significantly to >6500 independent observations in human, mouse, and rat tissues representing >4000 unique sites of modification. 136 The energized focus resulting from the technical innovation has resulted in some significant insights for the cardiovascular impact of these modifications. 137 For example, SNO-modified proteins have been found to modulate the Ca 2+ handling response in β-AR signaling. β-AR signaling is a critical component to modulate the caridomyocyte's calcium homeostasis; however, chronic stimulation can lead to the development of hypertrophy. 138 Irie et al 139 reported that S-nitrosylation of PLB at Cys 36 and 41 could suppress its inhibitory effect on SR Ca 2+ -ATPase, resulting in an increase of Ca 2+ to the SR. In the same study, the authors also found that S-nitrosylation of TnC at Cys 84 decreased myocardial sensitivity to Ca 2+ . They also observed a general decrease in SNO during the development of hypertrophy. These insights have led to a greater appreciation for the synergy between SNO and phosphorylation in this system. 139 Another SNO-modified protein is the glycolytic enzyme, GAPDH (glyceraldehyde-3-phosphate dehydrogenase). SNO modification has been previously been found to decrease its enzymatic activity; however, it has more recently been reported that GAPDH may have a role in the S-nitrosylation of mitochondrial proteins. 140, 141 Mitochondrial proteins in the heart are known to be S-nitrosylated although the source of the NO was not clear. Kohr et al 141 reported that SNO-modified GAPDH could translocate to the inner mitochondria and to transfer its NO group via transnitrosylation. The authors also observed that overexpression of GAPDH resulted in elevated SNO modification of several mitochondrial proteins. The examples described above, and many others, are all significant insights that have been facilitated by the introduction and continued refinement of a strategy for broad based screening of a PTM that was challenging to study by traditional means.
In contrast to SNO, some PTMs have remained less studied for lack of an effective large-scale identification strategy in a biologically relevant context. A recent example of a PTM with an emerging broad-based approach for identification is prenylation. Prenylation is the covalent addition of a lipid prenyl group to a cysteine residue near the C-terminus of a protein. Prenylation can take 2 forms: the addition of a farnesyl group (farnesylation) by a farnesyl transferase or 1 of 2 possible geranylgerany groups (geranylgeraylation) catalyzed by 2 different transferases (GGTase [geranylgeranyl transferase] I or II). Both involve the addition of an isoprenoid to a C-terminal Cys; farnesylation is composed of 15 carbons (204 Da), and the geranylgernayl group, 20 carbons (272 Da). 142 These modifications increase the protein's hydrophobicity and improve association with the cell membrane. For example, prenylation is required for Ras family GTPases and G-protein membrane localization. 143, 144 Modulation of protein prenylation has also been associated with cardiovascular regulation. Changes in prenylation have been linked to cardiac hypertrophy via an mTORC1 (mammalian target of rapamycin 1) mechanism leading to the development of chronic heart failure. 145 Conversely, Spindle et al 146 found that statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation. In both of these examples, no broad-based mapping of the changes in protein prenylation has been performed to determine their role in the specific deleterious or improved outcome.
One of the challenges facing the field is the difficulty in reliably identifying sites and discriminating between the 2 forms. In the past, study of prenylated proteins was performed on an individual protein basis using primarily radiographic techniques, which could take 2 months to visualize. MS analysis has also been challenging. The addition of a lipid group increases the hydrophobicity and reduces the ionization efficiency of a peptide. It has been reported that farnesylation can be observed by a 204-Da neutral loss during CID; however, this fragmentation has not been robust. 147, 148 Given these limitations, large-scale, comprehensive proteomic identification of this modification has been difficult indicating there is an opportunity for a technological innovation to significantly advance the field. One possibility could be seen in a recent proof-of-concept study by Bhawal et al. 148 In their study, the authors introduce an epoxidation with mCPBA (meta-chloroperoxybenzoic acid treatment) step to derivatize prenylated peptides before MS analysis. They report that the addition of an epoxy to the double bonds of the farnesyl or geranylgerany prenyl groups offers several advantages. First, it significantly improves the neutral loss fragmentation in CID. The authors and others found that mono-oxidation of a thioether bond resulted in the loss of specific sulfenic acid fragments. 148, 149 By evaluating the neutral loss product, it is possible to discriminate between a farnesyl and geranylgerany because of the 68-Da difference between them. The addition of the epoxy groups also significantly reduces the hydrophobicity of the prenylated peptides. This improves peptide solubility and ionization facilitating better MS identifications. Analyzing underivatized lipid-modified peptides using a reverse-phase LC-MS required long and high organic gradients. In a sample set of peptides, epoxidation resulted in significantly reduced retention times allowing for shorter separations. The final advantage of this approach is the possibility for an enrichment strategy. An azide can be added to epoxy-modified prenyl groups; this would allow for a click-chemistry addition of a biotin-alkyne group for specific capture of the prenylated peptides or proteins. Although this approach is still in an early phase, this type of advance will lead to greater access to the PTM in vivo, which will ultimately lead to a better understanding of its role in health and disease.
Another modification with important role in a variety of biological processes that has been difficult to study is citrullination. This modification results from the deamination of the guanidino group of arginine side chains to form an ureido group and the nonstandard amino acid citrulline. It is performed by a small family of enzymes known as peptidylarginine deiminase (PAD) 1, 2, 3, 4, and 6 on the basis of their cDNA nucleotide sequence. 150 Detection methods for PAD activity and citrullination are related, because conversion of arginine to citrulline in protein sequence is used as a readout for PAD activity. There are several assays available for the detection of PAD activity, such as colorimetric assay, 151 antibodybased assay (with antimodified citrulline antibodies), 152 or even direct MS analysis 153 ; however, none of them is specific, sensitive, and efficient enough to truly detect and identify modified residue. 154 The main challenge in MS detection of citrullinated proteins/peptides is exactly the same mass increase (0.9802 Da) as other PTM, deamidation. Those 2 modifications cannot be distinguished based on mass difference alone, and proper characterization of the exact citrullination site in the MS/MS spectrum, or additional information, is, therefore, required for peptides containing both potential deamidation and citrullination sites. Unfortunately, there is not currently an algorithm that will prevent false-positive assignment based on MS/MS data without manual, time-consuming verification.
Keeping in mind the technical difficulties, this modification increases the protein's hydrophobicity, creates neoantigens, and confers immunostimulatory properties. 155 For example, the autoimmune response is linked to the pathogenesis of several diseases, including rheumatoid arthritis, multiple sclerosis, and psoriasis. [156] [157] [158] [159] It has been also reported that the levels of citrullinated proteins and PAD4 were elevated in patients with various cancers, such as esophageal cancer, breast cancer, and lung adenocarcinoma. 160 A more recent work by Geraldino-Pardilla et al 161 reported that anticitrullinated proteins were detected and associated with left ventricular structure and function in rheumatoid arthritis. Fert-Bober et al 162 identified peptide regions of citrullination in major sarcomeric proteins indicating that this PTM may be functionally significant. Studies with knockout mice in an experimental model of cardiac fibrosis, cardiac pressure overload, support important role of PAD4 in neutrophil extracellular trap formation (netosis) in aged mice. 163 In this study, the author reported reduction in fibrosis in the hearts and lungs of aged PAD4−/− mice compared with wild-type mice. Furthermore, they found an increase in left ventricular interstitial collagen deposition and a decline in systolic and diastolic function only in wild-type mice, and not in PAD4−/− mice. 164 Contrariwise, Sokolove et al 165 found that citrullinated proteins are prevalent within the atherosclerotic plaque, and certain anticitrullinated protein antibodies are associated with atherosclerotic burden. 166 In both of these examples, the observations suggested that targeting of citrullinated epitopes or PAD enzyme itself could provide a mechanism for accelerated atherosclerosis.
This finding offers the potential for extensive further investigations attempting to sort out the complex modifications in health and disease.
There are many additional chemical PTMs that may ultimately prove of crucial diagnostic or therapeutic interest for a given pathophysiological event in cardiovascular disease. These include SUMOylation, [167] [168] [169] NEDDylation, 170, 171 ubiquitinylation, 172 palmitoylation, and other lipid modifications in addition to prenylation, 173 o-glcNAcylation, 174 and N-and O-linked glycosylation. 175, 176 As described for the examples above, improving the biochemical approaches for enriching or detecting PTMs, along with improving the ease and accessibility (eg, democratizing) of MS workflows for their detection and quantification by all cardiovascular scientists, will be critical before integration of proteoform knowledge into precision physiology can be truly implemented and translated to clinically relevant discoveries.
Conclusion and Moving Forward
The concept of democratization of MS means increasing the ability of the broader scientific community to use proteomic data, in part, through reducing the barriers to MS and data analysis software. 177 Proteomic analysis of human tissues has led to the realization that there are subsets of proteins that are closely involved in conserved pathophysiological processes seen across tissue and cell types. To take advantage of this concept, we have proposed that one strategy to democratize proteomics is to develop quantitative targeted MS-based assays to these pathways. These assays provide quantification equal to or better than ELISAs and Western blots, which are commonly used in basic science. Like their antibody-dependent counterparts, however, targeted assays are able to not only accurately quantify a specific protein abundance but they can also determine the site-specific ratio (stoichiometry) of a particular modified residue because of a SNP (single nucleotide polymorphism) or chemical PTMs, and they can be multiplexed to analyze between tens and hundreds of peptide analytes within a few (eg, <1-5) micrograms of a given sample. Thus, the potential is to be able to measure many proteoforms of interest in a straightforward, standardized, and quantitative method that is reproducible across many laboratories. Today, MS-based protein measurement is perceived as difficult and being owned by experts in academics or in MS-based laboratories. 109, 178 However, based on the existing proteomic technology, automation, and data software, this is doable (Figure 4) .
Once technical complexity is resolved, one other barrier to adoption is menu. It is not clear what proteins or pathways should be selected for producing these targeted assays. The National Cancer Institute has targeted several cancer pathways, 179, 180 and the community has produced standards and white papers for application of targeted assays as well. 51 But knowing which proteins and pathways to target in other disease areas or if there are conserved (and thus, high-valued targets) across diseases is not known. To address this challenge is the essence of initiative by the human proteome organization (http://www.hupo.org/B/D-HPP) to identify and then build assays for the most popular proteins used in different diseases. There is currently an ever-growing list of high-value protein targets at http://db.systemsbiology.net/sbeams/cgi/ PeptideAtlas/proteinListSelector, which will help the individual fields in cardiovascular disease and related diseases.
Popular proteins are defined as those proteins that have the highest citation number based on PubMed. These assays can be used for clinical translation and for basic science essentially supplementing ELISA and Western blots. The first article on this concept concentrated on heart, 181,182 but currently there are popular proteins for 6 organ systems 183 and also liver 184 with more to come. This brings up the second aspect required for democratization of proteomics. It is important that the broader community be informed about the proteoforms that can exist for their favorite protein or proteins and the tools available to access this information. For example, Table 2 lists 3 popular proteins that have been found to be modified by the less popularly studied PTM, citrullination. Here, we have highlighted known sites of modification that are also the sites of SNPs linked to cardiovascular disease. Similar disruption of critical function is apt to occur whenever a genomic event occurs at the site, or in close enough proximity for a biochemical impact, of a regulatory PTM. Thus, combining well-characterized information about a diversity of PTMs with well-annotated knowledge of sequence variants and their association with various diseases enables the most comprehensive linkage between sequence variation and its functional impact on all possible gene products. True precision profiling of any individuals' multiomic risk or treatment response profile will require a comprehensive catalogue of possible PTM sites and their regulatory impact on protein structure and function. A common route for integrated omic queries, such as this, is to use Uniprot or NeXtProt. However, new tools are continually being developed to help the user query the rapidly changing landscape Cit or R, deamidation of the guanidino group of arginine side chains to form a ureido group and the nonstandard amino acid Cit. The modified (Cit) and unmodified (R) peptides were observed by MS. 162 APOE indicates apolipoprotein E; Cit, citrullination; MS, mass spectrometry; TNNI3, troponin I3; and TNNT2, troponin T2.
of proteoforms to discover and target new aspects of the regulatory potential of their favorite protein or pathway. [185] [186] [187] [188] It is our goal as proteomics researchers to continue to reduce the technical barriers limiting the study of these complicated biochemical analytes across the greater scientific community. Considerably, more work is required to democratize proteomics including the need for open database sharing and integration alongside with bioinformatics tool for automatically validation of PTMs assignments, particularly from large-scale proteomic studies. These key processes will allow for the establishment of comprehensive databases; discover additional PTMs, chemical derivatives, and sample-specific amino acid variants. In conclusion, proteoforms highly, likely exist for every translated gene product. Studying the chemically derived proteoforms present in a physiological system is a technically challenging process often requiring biochemical enrichment, sophisticated MS, and bioinformatics tools. This is an exciting time, and it is a time to ensure that all aspects of proteomics together with other omics platform will also play a key role in understanding the extensive chemical diversity of biology.
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